Third Harmonic Bio Statistics
Share Statistics
Third Harmonic Bio has 45.06M shares outstanding. The number of shares has increased by 10.67% in one year.
| Shares Outstanding | 45.06M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 9.64% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 17.43M |
| Failed to Deliver (FTD) Shares | 60 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 3.35M, so 7.44% of the outstanding shares have been sold short.
| Short Interest | 3.35M |
| Short % of Shares Out | 7.44% |
| Short % of Float | 19.23% |
| Short Ratio (days to cover) | 14.29 |
Valuation Ratios
The PE ratio is -14.11 and the forward PE ratio is -9.85.
| PE Ratio | -14.11 |
| Forward PE | -9.85 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 1.62 |
| P/FCF Ratio | -21.12 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Third Harmonic Bio Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 50.29, with a Debt / Equity ratio of 0.
| Current Ratio | 50.29 |
| Quick Ratio | 50.29 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.11% and return on capital (ROIC) is -16.1%.
| Return on Equity (ROE) | -0.11% |
| Return on Assets (ROA) | -0.11% |
| Return on Capital (ROIC) | -16.1% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -604.39K |
| Employee Count | 51 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -42.03% in the last 52 weeks. The beta is 2.86, so Third Harmonic Bio 's price volatility has been higher than the market average.
| Beta | 2.86 |
| 52-Week Price Change | -42.03% |
| 50-Day Moving Average | 11.72 |
| 200-Day Moving Average | 12.27 |
| Relative Strength Index (RSI) | 20.78 |
| Average Volume (20 Days) | 219.42K |
Income Statement
| Revenue | n/a |
| Gross Profit | -35.00K |
| Operating Income | -43.95M |
| Net Income | -30.82M |
| EBITDA | -30.79M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.78 |
Balance Sheet
The company has 269.07M in cash and 3.95M in debt, giving a net cash position of 265.12M.
| Cash & Cash Equivalents | 269.07M |
| Total Debt | 3.95M |
| Net Cash | 265.12M |
| Retained Earnings | -114.22M |
| Total Assets | 304.49M |
| Working Capital | 293.17M |
Cash Flow
In the last 12 months, operating cash flow was -20.43M and capital expenditures -169.00K, giving a free cash flow of -20.59M.
| Operating Cash Flow | -20.43M |
| Capital Expenditures | -169.00K |
| Free Cash Flow | -20.59M |
| FCF Per Share | -0.52 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
THRD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -13% |
| FCF Yield | -7.62% |
Analyst Forecast
The average price target for THRD is $20, which is 233.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $20 |
| Price Target Difference | 233.3% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 31.28 |
| Piotroski F-Score | 3 |